Andreas Boeckl, founder, Dispersa Labs is bringing to the market Sula, breathable cannabis, which is inhaled from measured doses using a device that does not require combustion. This approach to dosing medical cannabis for specific conditions like neurological disorders, stress, anxiety, PTSD, and pain provides much faster relief than edible cannabis and allows for more flexibility for where the cannabis can be administered. Andreas also emphasizes the value of this solution for researchers who are studying the use of cannabinoids.
@breathesula #cannabis #BreatheSula #PTSD #cannabinoids
Breathesula.com
Download the transcript here
Empowered Patient Podcast